People: Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

3.70USD
21 Nov 2014
Price Change (% chg)

$0.45 (+13.85%)
Prev Close
$3.25
Open
$3.30
Day's High
$3.76
Day's Low
$3.29
Volume
4,330,557
Avg. Vol
892,528
52-wk High
$6.53
52-wk Low
$1.31

Search Stocks

Eastham, Karin 

Brief Biography

Ms. Karin Eastham is Independent Director of Geron Corporation. Ms. Eastham also serves as a director for MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company; Illumina, Inc., a manufacturer of life science tools and reagents; Trius Therapeutics, Inc., a biopharmaceutical company; and Veracyte, Inc., a privately held molecular diagnostics company. Ms. Eastham also served in the past five years as a director of Amylin Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 until its sale in 2011; Genoptix, Inc., a provider of specialized laboratory services, from 2008 until its sale in 2011; Tercica, Inc., a biopharmaceutical company, from 2003 until its sale in 2008; and SGX Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 until its sale in 2008. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham holds a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Hoyoung Huh

--

John Scarlett

2,278,340

Olivia Bloom

957,156

Stephen Rosenfield

883,374

Andrew Grethlein

866,575

Melissa Kelly Behrs

946,256
As Of 30 Dec 2013
Search Stocks